Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | IDE | P14735 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | EIF4A3 | P38919 | 4/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166201 | 1.00 | MDM2 (0.47) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL4168260 | 0.91 | MDM2 (0.48) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL4168266 | 0.91 | MDM2 (0.48) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL4167201 | 0.90 | MDM2 (0.47) | MDM2LMNAMAPK1MEN1IDE | |
| SCHEMBL4167196 | 0.90 | MDM2 (0.47) | MDM2LMNAMAPK1MEN1IDE | |
| SCHEMBL4163914 | 0.88 | MDM2 (0.46) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL4168355 | 0.84 | MDM2 (0.43) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL4168350 | 0.84 | MDM2 (0.43) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL13699574 | 0.84 | MDM2 (0.43) | MDM2LMNAMAPK1AKR1C3MEN1 | |
| SCHEMBL13699573 | 0.84 | MDM2 (0.44) | MDM2LMNAMAPK1AKR1C3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1960391-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | Vernalis (R&D) Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885LMNA 1997/4885MAPK1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.